| Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia S Soverini, S Colarossi, A Gnani, G Rosti, F Castagnetti, A Poerio, ... Clinical Cancer Research 12 (24), 7374-7379, 2006 | 639 | 2006 |
| Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia G Rosti, F Palandri, F Castagnetti, M Breccia, L Levato, G Gugliotta, ... Blood, The Journal of the American Society of Hematology 114 (24), 4933-4938, 2009 | 288 | 2009 |
| The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study M Baccarani, D Cilloni, M Rondoni, E Ottaviani, F Messa, S Merante, ... haematologica 92 (9), 1173-1179, 2007 | 242 | 2007 |
| Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) P Secchiero, E Barbarotto, M Tiribelli, C Zerbinati, MG di Iasio, A Gonelli, ... Blood 107 (10), 4122-4129, 2006 | 182 | 2006 |
| The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype D Damiani, M Tiribelli, E Calistri, A Geromin, A Chiarvesio, A Michelutti, ... Haematologica 91 (6), 825-828, 2006 | 151 | 2006 |
| Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study F Efficace, M Baccarani, G Rosti, F Cottone, F Castagnetti, M Breccia, ... British journal of cancer 107 (6), 904-909, 2012 | 128 | 2012 |
| Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party G Gugliotta, F Castagnetti, F Palandri, M Breccia, T Intermesoli, A Capucci, ... Blood, The Journal of the American Society of Hematology 117 (21), 5591-5599, 2011 | 125 | 2011 |
| Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ... Cancer 126 (6), 1243-1252, 2020 | 122 | 2020 |
| Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid … A Candoni, M Tiribelli, E Toffoletti, D Cilloni, A Chiarvesio, A Michelutti, ... European journal of haematology 82 (1), 61-68, 2009 | 119 | 2009 |
| Molecular response to imatinib in late chronic-phase chronic myeloid leukemia G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi, B Giannini, ... Blood 103 (6), 2284-2290, 2004 | 116 | 2004 |
| Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies A Candoni, R Mestroni, D Damiani, M Tiribelli, A Michelutti, F Silvestri, ... European journal of haematology 75 (3), 227-233, 2005 | 109 | 2005 |
| Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-192, 2015 | 101 | 2015 |
| Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism P Secchiero, E Melloni, MG di Iasio, M Tiribelli, E Rimondi, F Corallini, ... Blood, The Journal of the American Society of Hematology 113 (18), 4300-4308, 2009 | 99 | 2009 |
| Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission M Bocchia, A Sicuranza, E Abruzzese, A Iurlo, S Sirianni, A Gozzini, ... Frontiers in Oncology 8, 194, 2018 | 95 | 2018 |
| The BCR‐ABL1 transcript type influences response and outcome in P hiladelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib F Castagnetti, G Gugliotta, M Breccia, A Iurlo, L Levato, F Albano, ... American journal of hematology 92 (8), 797-805, 2017 | 93 | 2017 |
| Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases F Zaja, N Vianelli, A Sperotto, F Patriarca, M Tani, L Marin, M Tiribelli, ... Leukemia & lymphoma 44 (11), 1951-1955, 2003 | 92 | 2003 |
| Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells P Secchiero, C Zerbinati, M Grazia di Iasio, E Melloni, M Tiribelli, V Grill, ... Current drug metabolism 8 (4), 395-403, 2007 | 90 | 2007 |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP M Baccarani, E Abruzzese, V Accurso, F Albano, M Annunziata, S Barulli, ... Blood advances 3 (24), 4280-4290, 2019 | 81 | 2019 |
| Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia R Latagliata, M Breccia, C Fava, F Stagno, M Tiribelli, L Luciano, ... Hematological oncology 31 (2), 103-109, 2013 | 81 | 2013 |
| Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5-year outcome F Palandri, I Iacobucci, F Castagnetti, N Testoni, A Poerio, M Amabile, ... haematologica 93 (5), 770-774, 2008 | 81 | 2008 |
Giovanni MartinelliProfessor of Hematology "L. e A. Seragnoli" InstituteVerified email at unibo.it
